150 related articles for article (PubMed ID: 38341302)
41. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Tashakori M; Kadia T; Loghavi S; Daver N; Kanagal-Shamanna R; Pierce S; Sui D; Wei P; Khodakarami F; Tang Z; Routbort M; Bivins CA; Jabbour EJ; Medeiros LJ; Bhalla K; Kantarjian HM; Ravandi F; Khoury JD
Blood; 2022 Jul; 140(1):58-72. PubMed ID: 35390143
[TBL] [Abstract][Full Text] [Related]
42. p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.
Mueller S; Grote I; Bartels S; Kandt L; Christgen H; Lehmann U; Gluz O; Graeser M; Kates R; Harbeck N; Kreipe H; Christgen M
Mod Pathol; 2023 Apr; 36(4):100100. PubMed ID: 36788081
[TBL] [Abstract][Full Text] [Related]
43. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
44. Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.
Xu N; Lai YY; Chen WM; Jiang H; Wang Y; Wang X; Zhao XS; Huang XJ; Jiang Q; Qin YZ
Int J Lab Hematol; 2022 Oct; 44(5):892-899. PubMed ID: 35505580
[TBL] [Abstract][Full Text] [Related]
45. Nucleophosmin mutation analysis in acute myeloid leukaemia: Immunohistochemistry as a surrogate for molecular techniques.
Chopra A; Soni S; Pati H; Kumar D; Diwedi R; Verma D; Vishwakama G; Bakhshi S; Kumar S; Gogia A; Kumar R
Indian J Med Res; 2016 Jun; 143(6):763-768. PubMed ID: 27748301
[TBL] [Abstract][Full Text] [Related]
46. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
Köbel M; Kang EY
Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
[TBL] [Abstract][Full Text] [Related]
47. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
[TBL] [Abstract][Full Text] [Related]
48. [Clinical and prognostic values of TP53 mutation in patients with acute myeloid leukemia].
Zhang Y; Hu XX; Gao L; Ni X; Chen J; Chen L; Zhang WP; Yang JM; Wang JM
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):932-938. PubMed ID: 31856443
[No Abstract] [Full Text] [Related]
49. Deep Molecular and In Silico Protein Analysis of p53 Alteration in Myelodysplastic Neoplasia and Acute Myeloid Leukemia.
Madarász K; Mótyán JA; Bedekovics J; Miltényi Z; Ujfalusi A; Méhes G; Mokánszki A
Cells; 2022 Nov; 11(21):. PubMed ID: 36359870
[TBL] [Abstract][Full Text] [Related]
50. Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.
Oliva EN; Latagliata R; Sabattini E; Mammì C; Cuzzola M; D'Errigo MG; Cannatà MC; Bova I; Capodanno I; Palumbo GA; Pane F; Reda G; Fianchi L; Riva M; Poloni A
Am J Blood Res; 2021; 11(4):417-426. PubMed ID: 34540351
[TBL] [Abstract][Full Text] [Related]
51. High-resolution melting effectively pre-screens for TP53 mutations before direct sequencing in patients with diffuse glioma.
Saito K; Yokogami K; Maekawa K; Sato Y; Yamashita S; Matsumoto F; Mizuguchi A; Takeshima H
Hum Cell; 2021 Mar; 34(2):644-653. PubMed ID: 33454902
[TBL] [Abstract][Full Text] [Related]
52. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.
Siddon AJ; Weinberg OK
Clin Lab Med; 2023 Dec; 43(4):607-614. PubMed ID: 37865506
[TBL] [Abstract][Full Text] [Related]
53. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
54.
George B; Kantarjian H; Baran N; Krocker JD; Rios A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
[TBL] [Abstract][Full Text] [Related]
55. Optimized p53 immunohistochemistry is an accurate predictor of
Köbel M; Piskorz AM; Lee S; Lui S; LePage C; Marass F; Rosenfeld N; Mes Masson AM; Brenton JD
J Pathol Clin Res; 2016 Oct; 2(4):247-258. PubMed ID: 27840695
[No Abstract] [Full Text] [Related]
56. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM
J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067
[TBL] [Abstract][Full Text] [Related]
57. Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing.
Novak ER; Deshpande A; Finlay D; Mason JR; Deshpande AJ; Adams PD; Li S
Methods Mol Biol; 2023; 2594():87-95. PubMed ID: 36264490
[TBL] [Abstract][Full Text] [Related]
58. The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer.
Osakabe M; Yamada N; Sugimoto R; Uesugi N; Nakao E; Honda M; Yanagawa N; Sugai T
Virchows Arch; 2024 Mar; ():. PubMed ID: 38512505
[TBL] [Abstract][Full Text] [Related]
59. p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for
Li J; Wang J; Su D; Nie X; Liu Y; Teng L; Pang J; Wu H; Liang Z
Gastroenterol Res Pract; 2021; 2021():2510195. PubMed ID: 34956360
[TBL] [Abstract][Full Text] [Related]
60. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
